Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

The S&P 500 has soared in recent times, delivering two consecutive years of double-digit gains, and investors -- from ...

Bexhill’s De La Warr Pavilion presents Ssh Ow, the first major solo exhibition in a UK public gallery in a decade by ...

Genevant Sciences and Arbutus Biopharma (ABUS) filed five international lawsuits seeking to enforce patents protecting their innovative LNP ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

Highly pathogenic avian influenza continues to devastate poultry flocks throughout the United States, as well as cause ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

U.S. involvement in WHO flu meetings, the UK's approval of Moderna's RSV vaccine, efforts against a measles outbreak in Texas ...

US health officials are reviewing a nearly $600 million contract awarded to Moderna for bird flu vaccines in the final days ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for ...

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our ...